Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
LDB1
REST API REST API
Homo sapiens
LDB1 is differentially expressed in 240 experiments: 123 organism parts: prostate, bone marrow, ... (121 more);, 175 disease states: normal, chronic myelogenous leukemia, ... (173 more);, 61 cell types 306 cell lines 38 compound treatments and 65 other conditions.
Synonyms NLI, CLIM2
Orthologs ldb1a (Danio rerio)   LDB1_CHICK (Gallus gallus)   Ldb1 (Mus musculus)   LDB1 (Bos taurus)   Ldb1 (Rattus norvegicus)   ENSCING00000014405 (Ciona intestinalis)   Chi (Drosophila melanogaster)   ENSXETG00000001714 (Xenopus laevis)   LDB1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term neuron differentiation, DNA binding, negative regulation of transcription, DNA-dependent, protein binding, regulation of transcription, DNA-dependent, nuclear chromatin, cell-cell junction, protein complex, transcription, DNA-dependent, transcription corepressor activity, epithelial structure maintenance, transcription from RNA polymerase II promoter, anterior/posterior axis specification, positive regulation of transcription from RNA polymerase II promoter, Wnt receptor signaling pathway, multicellular organismal development, transcription cofactor activity, protein self-association, nucleus, somatic stem cell maintenance, chromatin binding, protein homodimerization activity, enzyme binding, positive regulation of cell adhesion, hair follicle development, cerebellum development, gastrulation with mouth forming second, LIM domain binding, negative regulation of erythrocyte differentiation, cerebellar Purkinje cell differentiation, head development, nucleoplasm part, regulation of transcription elongation, DNA-dependent, transcription-dependent tethering of RNA polymerase II gene DNA at nuclear periphery, transcription factor binding transcription factor activity, positive regulation of hemoglobin biosynthetic process, cellular component assembly, enhancer sequence-specific DNA binding, histone H3-K4 acetylation
InterPro Term LIM-bd
UniProt Accession Q86U70
Search EB-eye ENSG00000198728
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-GEOD-22541, ... (24 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-MTAB-62, E-GEOD-4219, ... (28 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-3529, E-GEOD-20081, E-GEOD-19639
A549
2
E-GEOD-3202, E-GEOD-6013
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
MDA468
2
E-MEXP-440, E-MTAB-62
PC3
2
E-MEXP-2034, E-GEOD-5258
skmc myoblast
1
E-MTAB-62
300 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-22373, E-GEOD-20677, E-GEOD-13909, E-GEOD-13987, ... (33 experiments)

Factor Value U/D Experiments
CD71+ early erythroid
2
E-AFMX-5, E-TABM-145
CD105+ endothelial
2
E-AFMX-5, E-TABM-145
fibroblast
2
E-GEOD-3204, E-GEOD-26672
neutrophil
1
E-GEOD-12662
single positive thymocyte
1
E-GEOD-1460
fetal RPE
1
E-GEOD-18811
55 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-15960, E-GEOD-1869, E-TABM-15, ... (41 experiments)

Factor Value U/D Experiments
chronic myelogenous leukemia
3
E-MTAB-37, E-MTAB-62, E-GEOD-5550
lung adenocarcinoma
3
E-MTAB-62, E-MTAB-37, E-GEOD-2514
acute lymphoblastic leukemia
2
E-MTAB-62, E-MTAB-37
colon carcinoma
2
E-MTAB-37, E-MTAB-62
squamous cell carcinoma
2
E-MTAB-62, E-MTAB-37
acute erythroid leukemia
1
E-GEOD-1729
169 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-6907, E-GEOD-15205, E-GEOD-697, E-GEOD-3720, ... (21 experiments)

Factor Value U/D Experiments
none
2
3
E-GEOD-5824, E-GEOD-20719, E-GEOD-412, E-GEOD-2803, E-GEOD-697 ... (5 experiments)
phenol
1
E-GEOD-6907
5-aza-2'-deoxycytidine
3
1
E-MEXP-1269
4,5-dianilinophthalimide
2
1
E-GEOD-5258
estradiol
1
E-GEOD-20081
ethanol
1
E-GEOD-3113
32 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
DMSO
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-GEOD-7967, E-TABM-125, E-GEOD-21589, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-21374, E-GEOD-4619, E-GEOD-21589, ... (7 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-5999, E-GEOD-3140, E-MEXP-2359, E-GEOD-6236, E-GEOD-2666, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-TABM-147, E-GEOD-21138

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-GEOD-7578

Genotype
studied in E-GEOD-17476, E-GEOD-21750, E-MEXP-421, E-GEOD-2292, E-TABM-321, ... (12 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-6432, E-GEOD-5681, E-GEOD-12773, E-MEXP-1446, ... (7 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-GEOD-20194, E-GEOD-16716

immunoprecipitated protein
studied in E-GEOD-21918

Individual
studied in E-MTAB-197, E-TABM-740, E-GEOD-1926, E-MEXP-2069, E-GEOD-10433, ... (29 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-12254

Injury
studied in E-GEOD-19743

Irradiate
studied in E-TABM-321

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-21750, E-GEOD-1657, E-MEXP-1403

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-19445, E-GEOD-19246

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10797, E-GEOD-18791

RNAi
studied in E-MEXP-2115, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, E-GEOD-3697, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Test result
studied in E-TABM-276, E-GEOD-2748

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 00 005
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-22541

Vehicle
studied in E-GEOD-5258

Processing time: 0.384 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM